The Latest Cardiac and Vascular News
SHANGHAI, March 28, 2023 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, announced the results from its PADN series study during the Late-Breaking Clinical Science (LBCS) session of the second Technology and Heart Failure Therapeutics (THT 2023), with the presentation of its follow-up findings from PADN-5 study. As the first […]
CAUTION: Investigational device. Limited by United States law to investigational use. FIRST U.S. PATIENT ENROLLED IN GORE® VIAFORT Vascular Stent pivotal study FLAGSTAFF, Ariz., March 28, 2023 /PRNewswire/ — W. L. Gore & Associates (Gore) has announced that the first U.S. patient has been enrolled in a prospective, non-randomized, multicenter, single-arm study with 5-year […]
BOSTON, March 28, 2023 /PRNewswire/ — CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, names Adel Malek, MD PhD as the company’s Chief Medical Officer. This new appointment will allow CereVasc to further accelerate the development and clinical strategy of the eShunt® System, the first […]
NEWTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for Q4 and full year ended December 31, 2022, and […]
Deal gives Silence exclusive worldwide rights to two siRNA complement assets LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced it will be acquiring back exclusive worldwide rights to […]
Growth-focused leader will help bring the company’s AI-powered cardiovascular technology to market BOSTON–(BUSINESS WIRE)–Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Andrew Miller as its chief technology officer (CTO). In this role, Andrew will lead the technological strategy and […]
– JK07 Advancing into Phase 2 Clinical Trial in Heart Failure with Reduced Ejection Fraction (HFrEF); Topline Phase 1b Results Expected in 1H 2023 – –Fourth Cohort Enrolling in Phase 1/2 Study Evaluating JK08 Monotherapy in Advanced Solid Tumors; Favorable Pharmacodynamic Activities Observed Across Cohorts – GAITHERSBURG, Md.–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology […]
Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the appointment of […]
Peer-reviewed study published in Frontiers of Physiology presents the use of Biobeat’s chest patch and novel warning score (MPRT-WS) to predict patient outcomes MPRT-WS more accurate in stratifying patients at risk of deterioration than the clinically-used National Early Warning Score (NEWS) Biobeat to host a demo booth (#2037) at ViVE® 2023 from March […]
SAFE-MCS Examines the Impact of the Early Bird® Bleed Monitoring System on Reducing Bleeding Complications in Patients Undergoing High Risk PCI with Mechanical Circulatory Support HOUSTON–(BUSINESS WIRE)–Saranas, Inc. announced today that it has reached the midpoint for enrollment in SAFE-MCS, a multi-center, single arm, open-label clinical trial evaluating the safety […]
